QBCF-TMAC is a program that regroups together several samples of breast cancer patients from three institutions (CHUM, MUHC and CHUQ). It is assembling a cohort of 2,000 breast cancer samples on tissue micro-arrays (TMA). Please see the attached service description and application form in "SERVICES" section

Large-scale biobanking in research

In 2014, Exactis Innovations was created thanks to a $15 million grant awarded to Dr. G. Batist from SSHRC-CIHR-NSERC and with another $15 million from private and public organizations worldwide. This large-scale biobanking effort aims to be active across Canada and already includes multiple Quebec centers such as the CHUM, CHUS, and CHUQ. By creating a much larger database and platform accessible to many, Exactis hopes to create a shift in how we classify patients and identify appropriate groups for clinical trials. In turn, this could lead to an increased rate of cancer targets being discovered and which would accelerate the development and implementation of new treatments in Canada.


Collaboration with Ovarian Cancer Canada (OCC)

Ovarian Cancer Canada (OCC) continues its contribution to the RRCancer for its banking activities. This donation will be used to support the efforts of researchers in banking ovarian tissues for research purposes.

The RRCancer warmly thanks the OCC for its generous contribution.

The Quebec Breast Cancer Foundation announces an important contribution with the RRCancer

We are pround to announce that the breast cancer biobanking activities of the RRCancer have received an important contribution. The Quebec Breast Cancer Foundation has committed $1 million over four years to support the collection of biological tissues (normal breast tissue, breast tumors, blood) and pertinent clinical data from women who consent to participate in the program. These monies will be shared by the five major breast cancer banking sites of the RRCancer at the MUHC, CHUM, CHUQ, CHA and the CHUS.

In addition, this contribution will allow us to develop a new program to bank circulating tumor cells from the blood of breast cancer patients. These cancer cells found in the blood are thought to represent the cells able to seed distant organs and initiate the metastatic disease which is associated with poor outcomes.